Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Dr Reddy’s Laboratories ( (RDY) ) is now available.
On March 21, 2026, Dr. Reddy’s Laboratories launched Obeda, India’s first Drugs Controller General of India–approved generic semaglutide injection for type 2 diabetes, marking a Day-1 entry into the GLP-1 receptor agonist space. Developed fully in-house, Obeda is positioned to expand access to advanced diabetes care for India’s more than 100 million adults living with the disease.
In a Phase III trial with 312 participants, Obeda demonstrated non-inferior efficacy and a comparable safety and immunogenicity profile to the innovator drug, including similar reductions in HbA1c and glucose control measures. The once-weekly pre-filled pen, available in 2 mg and 4 mg strengths at an estimated cost of INR 4,200 per month, is backed by a digital patient support program and plans for metabolic centres of excellence as Dr. Reddy’s builds a full GLP-1 portfolio and targets launches of generic semaglutide in additional countries, subject to approvals.
The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a global pharmaceutical company based in Hyderabad, India, with listings in Mumbai, New York and on other exchanges, focused on branded and generic medicines. The company has built decade-long expertise in peptide science and complex product development, with a growing emphasis on metabolic disorders such as type 2 diabetes and obesity.
Average Trading Volume: 1,869,013
Technical Sentiment Signal: Hold
Current Market Cap: $11.56B
For an in-depth examination of RDY stock, go to TipRanks’ Overview page.